Denosumab Essay

875 Words4 Pages
BUS 690 Case #2: Forecasting Denosumab Amgen – was one of the world’s leading biotechnology companies, with more than 17,000 employees and almost $15 billion in revenue. Amgen’s most important drugs include: * Aranesp-anemia; declining sharply * Epogen-anemia * Enbrel-arthritis * Neulasta-febrile neutropenia, a condition associated with chemotherapy Amgen has developed a new product called Denosumab under brand names Prolia and Xgeva, and had patents that were scheduled to expire between 2017 and 2023. Prolia treats Osteoporosis, a bone disorder, common but serious condition. Xgeva seeks to prevent skeletal-related events from occurring in cancer patients with bone metastases. Prolia Osteoporosis is diagnosed by BMD—bone mineral density test, the primary BMD test was dual-energy X-ray absorptiometry (DXA); a BMD test costs $50 per patient. Amgen priced Prolia at $825 per injection, or $1,650 per year. There is a total of 30.7 million people in the U.S. with osteoporosis or osteopenia, and 15.5 million (49%) were diagnosed, only a portion of that group received treatment. 40% of patients receiving treatment continued to see declining BMD levels, and 5% had fractures. Aside from treatment options of exercise and dietary supplements, bisphosphonates are the main class of drugs for the treatment of osteopenia and osteoporosis in early 2011, made from two phosphonic groups. The drugs worked by slowing the breakdown of bone by osteoclasts, resulting in an increase in BMD and a decrease in fractures. Despite the strong efficacy of bisphosphonates, compliance was low; studies indicated that about 50% of patients discontinued oral bisphosphonate therapy within the first year. Prolia’s competition: | U.S. Sales (mil) | Year | Boniva | $600.00 | 2008 | Reclast | $579.00 | 2010 | Evista | $682.00 | 2009 | Forteo |

More about Denosumab Essay

Open Document